GMAB News and Press, Genmab A/S From 05/23/24

Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with difficult-to-treat lymphomas across multiple lines of therapy and histologies where high unmet needs exist Results from two studies evaluating tisotumab ...

Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms ...

Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development program Three oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combinati...

2024-05-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...

2024-05-02 18:05:20 ET Genmab A/S (GMAB) Q1 2024 Earnings Conference Call May 2, 2024 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Mancini – Chief Operating Officer Anthony Pagano – Chief Financial Offi...

May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-01 14:28:01 ET More on Genmab Genmab: A Complicated Tale Genmab Acquires A Missing Piece For Its Pipeline Genmab: Recent Updates Support The Growth Narrative Pfizer, Genmab cervical cancer therapy wins full FDA approval Genmab to purchase US-b...

2024-05-01 11:22:41 ET Major earnings expected before the bell on Thursday include: ConocoPhillips ( COP ) Iron Mountain ( IRM ) Moderna ( MRNA ) Organon ( OGN ) Shell ( SHEL ) Read the full article on Seeking Alpha For further details...